The AHA again expressed concern to the Department of Health and Human Services about recent actions taken by several major drug manufacturers to limit the distribution of certain 340B drugs to hospitals. 

While the Health Resources and Services Administration, which oversees the 340B program, is investigating these activities, AHA urged HHS to take “swift and decisive action to halt these pernicious tactics” to prevent other manufacturers from following suit.

“The drug companies are attempting to exploit for their financial benefit the current COVID-19 health care crisis,” AHA said. “As you are aware, hospitals throughout the nation are under severe stress by the need to prepare for, and/or care for, COVID-19 patients, while coping with the financial damages inflicted by the virus. Therefore, we urge you to act immediately against any drug manufacturer employing these pernicious tactics to ensure that 340B drugs are available and accessible to vulnerable communities.” Read the full letter here.

The AHA has engaged in numerous efforts urging the drug companies to cease these activities and have HHS take action to protect 340B hospitals. See the previous letters the AHA has sent on the issue:

Related News Articles

Headline
The AHA, joined by member hospitals and health systems and other national organizations representing hospitals, today filed reply briefs in their petitions…
Headline
State and regional hospital associations today filed friend-of-the-court briefs supporting AHA’s request for the U.S. Supreme Court to review two circuit court…
Headline
Instead of attacking hospitals and health systems caring for patients during the COVID-19 pandemic, PhRMA should instead focus on lowering the costs of drugs…
Headline
The AHA, joined by member hospitals and health systems and other national organizations representing hospitals, yesterday filed petitions asking the U.S.…
Blog
America’s hospitals and health systems, and our heroic caregivers, have been on the front lines of the battle against COVID-19 for the past year, working…
Headline
The AHA, joined by four other national hospital groups and hospital pharmacists representing participants in the 340B drug pricing program, Friday filed a…